Wnt Inhibitors DKK1 and SFRP Why Your Follicles Cannot Ac…

The Brakes on Hair Growth: Wnt Inhibitors

Wnt/β-catenin signaling is the master regulator of hair follicle growth — it is the pathway that tells stem cells to activate, drives keratinocyte proliferation, and maintains the anagen phase. But every accelerator needs a brake, and in the hair follicle, the primary brakes on Wnt signaling are Dickkopf-1 (DKK1) and Secreted Frizzled-Related Proteins (SFRPs). When these inhibitors are overexpressed, they create a molecular environment where follicles cannot activate anagen — no matter how much Wnt ligand is present. Understanding Wnt inhibition is essential for understanding why some follicles remain permanently dormant.

Wnt Inhibitors DKK1 and SFRP Why Your Follicles Cannot Activate Anagen

The importance of Wnt inhibitors in hair biology was established by a 2007 study from the Cotsarelis laboratory showing that DKK1 expression is elevated in the scalp of patients with androgenetic alopecia. Also, they demonstrated that DHT upregulates DKK1 expression in dermal papilla cells, providing a direct mechanistic link between androgen signaling and Wnt pathway suppression.

DKK1: The Potent Wnt Antagonist

DKK1 is a secreted protein that specifically inhibits canonical Wnt signaling by binding to the Wnt co-receptors LRP5 and LRP6. Here is how it works:

The Wnt Receptor Complex

Canonical Wnt signaling requires a receptor complex consisting of:

Frizzled (Fzd): The primary Wnt receptor
LRP5/6: Co-receptor essential for signal transduction

When Wnt binds to both Frizzled and LRP5/6, it triggers the destabilization of the β-catenin destruction complex (Axin, APC, GSK3β, CK1), allowing β-catenin to accumulate and translocate to the nucleus.

How DKK1 Blocks This

DKK1 binds to LRP5/6 with high affinity, competing with Wnt for co-receptor access. It also recruits another membrane protein called Kremen, which triggers the internalization and degradation of LRP5/6. This effectively removes the co-receptor from the cell surface, rendering the cell insensitive to Wnt — even if Wnt ligand is abundant.

DKK1 in Androgenetic Alopecia

In balding scalp, DKK1 is produced by:

Dermal papilla cells: DHT directly upregulates DKK1 transcription through androgen receptor signaling
Outer root sheath keratinocytes: Inflammatory cytokines (TNF-α, IL-1) induce DKK1 expression
Sebaceous gland cells: Produce DKK1 as part of their Wnt-modulating function

The result is a perifollicular environment rich in DKK1 that effectively suppresses Wnt/β-catenin signaling, preventing anagen initiation and maintenance.

SFRPs: The Decoy Receptors

SFRPs are another family of Wnt inhibitors with a different mechanism. They contain a cysteine-rich domain (CRD) that is homologous to the Wnt-binding domain of Frizzled receptors, but they lack the transmembrane and intracellular signaling domains. SFRPs function as decoy receptors:

SFRP1

The most studied SFRP in hair biology. SFRP1 binds Wnt ligands in the extracellular space, preventing them from reaching their true Frizzled receptors. In the hair follicle:

SFRP1 is expressed in the bulge stem cell niche during telogen
It helps maintain stem cell quiescence by preventing Wnt activation
In androgenetic alopecia, SFRP1 expression may be inappropriately maintained, preventing stem cell activation
Mice lacking SFRP1 show precocious anagen entry, confirming its role as a physiological Wnt brake

SFRP2 and SFRP4

These SFRPs are also expressed in hair follicle tissue and may contribute to Wnt suppression in balding scalp. SFRP2 has been shown to inhibit hair follicle development in embryonic skin, and its expression is elevated in the perifollicular dermis of balding scalp.

The DHT-DKK1-Wnt Axis

The connection between DHT and Wnt inhibition through DKK1 represents one of the most important mechanistic explanations for androgenetic alopecia:

DHT activates the androgen receptor in dermal papilla cells
AR signaling upregulates DKK1 transcription
DKK1 is secreted and binds LRP5/6 on neighboring epithelial cells
Wnt signaling is suppressed in these cells
β-catenin cannot accumulate and translocate to the nucleus
Anagen genes are not activated
Follicles remain in or revert to telogen

This axis explains several clinical observations:

Why finasteride works: By reducing DHT, it reduces DKK1 production, partially restoring Wnt signaling
Why finasteride is not always sufficient: Even with reduced DHT, other sources of DKK1 (inflammation, aging) persist
Why combination therapy may be needed: Addressing DHT alone does not fully restore the Wnt-activating environment

Therapeutic Approaches Targeting Wnt Inhibitors

Anti-DKK1 Antibodies

Neutralizing antibodies against DKK1 could block its interaction with LRP5/6, restoring Wnt signaling. A 2013 study showed that anti-DKK1 antibody treatment increased β-catenin signaling in hair follicle organ culture and promoted anagen. However, systemic DKK1 blockade could have unintended effects on bone metabolism (DKK1 is a key regulator of bone formation), making topical application essential.

Small Molecule DKK1 Inhibitors

Several pharmaceutical companies have developed small molecule DKK1 inhibitors for osteoporosis. These compounds could potentially be reformulated for topical scalp use. WAY-262611 and related compounds have shown DKK1 inhibitory activity in preclinical studies.

SFRP Inhibition

Approaches to block SFRPs are less developed but could include:

Anti-SFRP1 antibodies: Would prevent SFRP1 from sequestering Wnt ligands
SFRP-binding peptides: Could neutralize SFRPs in the perifollicular space

Lithium and GSK3β Inhibition

Lithium chloride inhibits GSK3β, a component of the β-catenin destruction complex. By inhibiting GSK3β, lithium stabilizes β-catenin regardless of upstream Wnt/DKK1 signaling. While oral lithium is not appropriate for hair loss (due to toxicity), topical lithium formulations have shown hair growth-promoting effects in animal models by bypassing DKK1-mediated Wnt inhibition.

Wnt Activators That Bypass DKK1

Some Wnt pathway activators work downstream of the receptor complex and are therefore resistant to DKK1 inhibition:

CHIR99021: A GSK3β inhibitor that activates β-catenin regardless of upstream Wnt/DKK1 status
Lithium chloride: As discussed above
SB216763: Another GSK3β inhibitor

Practical Implications

DKK1 is the primary brake on hair follicle Wnt signaling — and DHT directly increases DKK1 production, linking androgen signaling to Wnt suppression.
Even with normal Wnt ligand levels, DKK1 can prevent pathway activation — it is a dominant inhibitor that renders cells Wnt-insensitive.
Finasteride partly works by reducing DKK1 — the Wnt restoration is one mechanism of its efficacy.
Anti-DKK1 therapy could be the next major hair loss treatment — blocking DKK1 restores Wnt signaling without the systemic effects of Wnt agonists.
GSK3β inhibitors can bypass DKK1 — by acting downstream of the receptor, they activate β-catenin regardless of upstream inhibition.
The DHT-DKK1-Wnt axis explains why some patients do not respond to anti-androgens alone — their DKK1 may be driven by inflammation or other factors independent of DHT.

The Therapeutic Potential of Combined Wnt Activation and DKK1 Inhibition

Given that DKK1 and SFRPs create a multi-layered brake on Wnt signaling, the most effective therapeutic approach may involve simultaneously reducing Wnt inhibition (through DKK1/SFRP blockade) and enhancing Wnt activation (through direct pathway agonists). This dual approach could produce synergistic effects greater than either strategy alone.

A 2022 preclinical study tested this concept using a combination of anti-DKK1 antibody and a GSK3β inhibitor in mouse skin. The combination produced significantly more robust hair growth than either treatment alone, with treated animals showing earlier anagen entry and longer anagen duration.

The mechanistic rationale for this synergy is clear:

DKK1 blockade removes the brake on Wnt signaling, allowing endogenous Wnt ligands to activate their receptors
GSK3β inhibition activates β-catenin downstream of the receptor, ensuring pathway activation even if some DKK1 remains or other Wnt inhibitors are present

Together, these approaches address both the receptor-level blockade (DKK1) and the intracellular signal attenuation (GSK3β-mediated β-catenin degradation) that suppress Wnt signaling in balding scalp.

For clinical translation, a topical formulation containing both a DKK1-neutralizing agent and a GSK3β inhibitor would be needed. While no such product exists commercially, the individual components have been validated in preclinical models, and the combination approach is a logical next step.

PDGF in Wound Healing and Follicle Neogenesis

The role of PDGF in follicle neogenesis — the creation of new hair follicles in adult skin after wounding — has been demonstrated in mouse models. When large full-thickness wounds are created in mouse skin, the healing process occasionally produces new follicles through a Wnt-dependent pathway. PDGF signaling is required for this neogenesis: wounds in mice with platelet-specific PDGF deletion produce significantly fewer new follicles than control wounds. This finding suggests that PDGF could be a key component of therapies aimed at inducing new follicle formation in bald areas.

Wnt Inhibitors DKK1 and SFRP Why Your Follicles Cannot Activate Anagen